Published in PLoS One on December 07, 2012
Reduced expression of miRNA-27a modulates cisplatin resistance in bladder cancer by targeting the cystine/glutamate exchanger SLC7A11. Clin Cancer Res (2014) 1.16
From microRNA functions to microRNA therapeutics: novel targets and novel drugs in breast cancer research and treatment (Review). Int J Oncol (2013) 1.06
Tumor suppressor microRNA-27a in colorectal carcinogenesis and progression by targeting SGPP1 and Smad2. PLoS One (2014) 0.99
MiR-138 Suppresses Cell Proliferation by Targeting Bag-1 in Gallbladder Carcinoma. PLoS One (2015) 0.90
α-Synuclein overexpression represses 14-3-3θ transcription. J Mol Neurosci (2013) 0.81
High microRNA-23a expression in laryngeal squamous cell carcinoma is associated with poor patient prognosis. Diagn Pathol (2015) 0.81
c-MYC Generates Repair Errors via Increased Transcription of Alternative-NHEJ Factors, LIG3 and PARP1, in Tyrosine Kinase-Activated Leukemias. Mol Cancer Res (2015) 0.80
Targeting oncomiRNAs and mimicking tumor suppressor miRNAs: Νew trends in the development of miRNA therapeutic strategies in oncology (Review). Int J Oncol (2016) 0.79
Comprehensive Expression Profiling and Functional Network Analysis of p53-Regulated MicroRNAs in HepG2 Cells Treated with Doxorubicin. PLoS One (2016) 0.79
miR-27a promotes cell proliferation and metastasis in renal cell carcinoma. Int J Clin Exp Pathol (2015) 0.79
Uncovering low-dimensional, miR-based signatures of acute myeloid and lymphoblastic leukemias with a machine-learning-driven network approach. Converg Sci Phys Oncol (2015) 0.78
MiR-424 and miR-27a increase TRAIL sensitivity of acute myeloid leukemia by targeting PLAG1. Oncotarget (2016) 0.78
Emerging role of microRNAs in cancer stem cells: Implications in cancer therapy. World J Stem Cells (2015) 0.76
Methylation Status of SP1 Sites within miR-23a-27a-24-2 Promoter Region Influences Laryngeal Cancer Cell Proliferation and Apoptosis. Biomed Res Int (2016) 0.76
A step-by-step microRNA guide to cancer development and metastasis. Cell Oncol (Dordr) (2017) 0.75
High Expression of CPT1A Predicts Adverse Outcomes: A Potential Therapeutic Target for Acute Myeloid Leukemia. EBioMedicine (2016) 0.75
The functional role of microRNA in acute lymphoblastic leukemia: relevance for diagnosis, differential diagnosis, prognosis, and therapy. Onco Targets Ther (2015) 0.75
MiRNA-27a promotes the proliferation and invasion of human gastric cancer MGC803 cells by targeting SFRP1 via Wnt/β-catenin signaling pathway. Am J Cancer Res (2017) 0.75
Regulatory miRNAs in Colorectal Carcinogenesis and Metastasis. Int J Mol Sci (2017) 0.75
High expression of MAP7 predicts adverse prognosis in young patients with cytogenetically normal acute myeloid leukemia. Sci Rep (2016) 0.75
MicroRNAs as Biomarkers in Colorectal Cancer. Cancers (Basel) (2017) 0.75
MicroRNAs: genomics, biogenesis, mechanism, and function. Cell (2004) 198.59
Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell (2005) 96.87
MicroRNAs: target recognition and regulatory functions. Cell (2009) 92.17
Combinatorial microRNA target predictions. Nat Genet (2005) 50.48
Genome-scale DNA methylation maps of pluripotent and differentiated cells. Nature (2008) 30.29
miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci U S A (2005) 21.51
The microRNA.org resource: targets and expression. Nucleic Acids Res (2007) 16.26
The UCSC Genome Browser database: update 2011. Nucleic Acids Res (2010) 16.24
A pattern-based method for the identification of MicroRNA binding sites and their corresponding heteroduplexes. Cell (2006) 14.70
c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism. Nature (2009) 13.28
Widespread microRNA repression by Myc contributes to tumorigenesis. Nat Genet (2007) 10.78
MicroRNAs to Nanog, Oct4 and Sox2 coding regions modulate embryonic stem cell differentiation. Nature (2008) 9.83
Gene silencing by microRNAs: contributions of translational repression and mRNA decay. Nat Rev Genet (2011) 9.79
MiR-150 controls B cell differentiation by targeting the transcription factor c-Myb. Cell (2007) 9.33
MicroRNA-34a functions as a potential tumor suppressor by inducing apoptosis in neuroblastoma cells. Oncogene (2007) 6.55
miR-34a repression of SIRT1 regulates apoptosis. Proc Natl Acad Sci U S A (2008) 6.24
miRNAs in human cancer. J Pathol (2010) 6.02
MicroRNAs in cancer: small molecules with a huge impact. J Clin Oncol (2009) 5.92
MicroRNAs 221 and 222 inhibit normal erythropoiesis and erythroleukemic cell growth via kit receptor down-modulation. Proc Natl Acad Sci U S A (2005) 5.54
MicroRNA let-7a down-regulates MYC and reverts MYC-induced growth in Burkitt lymphoma cells. Cancer Res (2007) 5.25
miR-24 Inhibits cell proliferation by targeting E2F2, MYC, and other cell-cycle genes via binding to "seedless" 3'UTR microRNA recognition elements. Mol Cell (2009) 5.22
Oncogenic activity of the c-Myc protein requires dimerization with Max. Cell (1993) 4.10
CD34+ hematopoietic stem-progenitor cell microRNA expression and function: a circuit diagram of differentiation control. Proc Natl Acad Sci U S A (2007) 4.06
The 14-3-3 proteins: integrators of diverse signaling cues that impact cell fate and cancer development. Trends Cell Biol (2008) 3.30
MicroRNA 29b functions in acute myeloid leukemia. Blood (2009) 3.19
MicroRNA expression signatures accurately discriminate acute lymphoblastic leukemia from acute myeloid leukemia. Proc Natl Acad Sci U S A (2007) 3.00
Reprogramming of miRNA networks in cancer and leukemia. Genome Res (2010) 2.65
Human microRNA clusters: genomic organization and expression profile in leukemia cell lines. Biochem Biophys Res Commun (2006) 2.65
Low molecular weight inhibitors of Myc-Max interaction and function. Oncogene (2003) 2.57
MicroRNA miR-24 inhibits erythropoiesis by targeting activin type I receptor ALK4. Blood (2007) 2.40
Transcriptional suppression of mir-29b-1/mir-29a promoter by c-Myc, hedgehog, and NF-kappaB. J Cell Biochem (2010) 2.30
Cooperative and individualistic functions of the microRNAs in the miR-23a~27a~24-2 cluster and its implication in human diseases. Mol Cancer (2010) 2.14
A small-molecule c-Myc inhibitor, 10058-F4, induces cell-cycle arrest, apoptosis, and myeloid differentiation of human acute myeloid leukemia. Exp Hematol (2006) 1.94
Lentiviral vectors with two independent internal promoters transfer high-level expression of multiple transgenes to human hematopoietic stem-progenitor cells. Mol Ther (2003) 1.87
14-3-3 Interacts directly with and negatively regulates pro-apoptotic Bax. J Biol Chem (2002) 1.84
MicroRNA patterns associated with clinical prognostic parameters and CNS relapse prediction in pediatric acute leukemia. PLoS One (2009) 1.62
Upregulation of miR-23a-27a-24-2 cluster induces caspase-dependent and -independent apoptosis in human embryonic kidney cells. PLoS One (2009) 1.54
A regulatory interplay between miR-27a and Runx1 during megakaryopoiesis. Proc Natl Acad Sci U S A (2008) 1.44
CD34+CD38+CD19+ as well as CD34+CD38-CD19+ cells are leukemia-initiating cells with self-renewal capacity in human B-precursor ALL. Leukemia (2008) 1.39
Acute myeloid leukemia stem cells. Ann N Y Acad Sci (2005) 1.32
Transcriptional repression of microRNA genes by PML-RARA increases expression of key cancer proteins in acute promyelocytic leukemia. Blood (2008) 1.30
Unique molecular and cellular features of acute myelogenous leukemia stem cells. Leukemia (2002) 1.23
MIR-23A microRNA cluster inhibits B-cell development. Exp Hematol (2010) 1.19
Arginine methylation of BCL-2 antagonist of cell death (BAD) counteracts its phosphorylation and inactivation by Akt. Proc Natl Acad Sci U S A (2011) 1.15
High frequencies of leukemia stem cells in poor-outcome childhood precursor-B acute lymphoblastic leukemias. Leukemia (2010) 1.13
Downregulation of BCL2 by miRNAs augments drug-induced apoptosis--a combined computational and experimental approach. J Cell Sci (2012) 1.13
Down-regulated miR-331-5p and miR-27a are associated with chemotherapy resistance and relapse in leukaemia. J Cell Mol Med (2011) 1.13
Potential tumor suppressive function of miR-196b in B-cell lineage acute lymphoblastic leukemia. Mol Cell Biochem (2010) 1.10
miR-24-2 controls H2AFX expression regardless of gene copy number alteration and induces apoptosis by targeting antiapoptotic gene BCL-2: a potential for therapeutic intervention. Breast Cancer Res (2011) 1.10
A set of miRNAs that involve in the pathways of drug resistance and leukemic stem-cell differentiation is associated with the risk of relapse and glucocorticoid response in childhood ALL. Hum Mol Genet (2011) 1.07
c-Myc inhibition negatively impacts lymphoma growth. J Pediatr Surg (2006) 1.05
Interdependent regulation of p53 and miR-34a in chronic lymphocytic leukemia. Cell Cycle (2010) 0.97
Genome-wide analysis of small RNA and novel MicroRNA discovery in human acute lymphoblastic leukemia based on extensive sequencing approach. PLoS One (2009) 0.96
14-3-3 gamma is stimulated by IL-3 and promotes cell proliferation. J Immunol (2009) 0.86
Isoform-specific cleavage of 14-3-3 proteins in apoptotic JURL-MK1 cells. J Cell Biochem (2009) 0.85
Systematic localization of common disease-associated variation in regulatory DNA. Science (2012) 14.47
Notch-mediated expansion of human cord blood progenitor cells capable of rapid myeloid reconstitution. Nat Med (2010) 5.84
IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol (2010) 5.62
Characterization of clonogenic multiple myeloma cells. Blood (2003) 5.35
Aldehyde dehydrogenase 1 is a tumor stem cell-associated marker in lung cancer. Mol Cancer Res (2009) 4.36
Prognostic significance of the European LeukemiaNet standardized system for reporting cytogenetic and molecular alterations in adults with acute myeloid leukemia. J Clin Oncol (2012) 4.34
CD34+ hematopoietic stem-progenitor cell microRNA expression and function: a circuit diagram of differentiation control. Proc Natl Acad Sci U S A (2007) 4.06
Mobile interspersed repeats are major structural variants in the human genome. Cell (2010) 3.60
HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignancies. Blood (2003) 3.30
Single-unit dominance after double-unit umbilical cord blood transplantation coincides with a specific CD8+ T-cell response against the nonengrafted unit. Blood (2009) 3.05
TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol (2011) 3.01
Wilms' tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study. J Clin Oncol (2008) 2.98
Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: a Cancer and Leukemia Group B study. J Clin Oncol (2009) 2.78
A clinical drug library screen identifies astemizole as an antimalarial agent. Nat Chem Biol (2006) 2.72
Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse. Blood (2011) 2.66
ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category. Blood (2011) 2.50
Overexpression of the ETS-related gene, ERG, predicts a worse outcome in acute myeloid leukemia with normal karyotype: a Cancer and Leukemia Group B study. J Clin Oncol (2005) 2.41
ALDH1A1 is a marker for malignant prostate stem cells and predictor of prostate cancer patients' outcome. Lab Invest (2009) 2.25
Signal transducer and activator of transcription proteins in leukemias. Blood (2002) 2.23
Notch inhibits Ptf1 function and acinar cell differentiation in developing mouse and zebrafish pancreas. Development (2004) 2.21
Early detection of lung adenocarcinoma in sputum by a panel of microRNA markers. Int J Cancer (2010) 2.20
Kinetics of engraftment in patients with hematologic malignancies given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. Blood (2004) 2.18
Altered miRNA expression in sputum for diagnosis of non-small cell lung cancer. Lung Cancer (2009) 2.14
Tertiary center referral patterns for patients with myelodysplastic syndrome are indicative of age and race disparities: a single-institution experience. Leuk Lymphoma (2012) 2.14
Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the alternative dosing for outpatient treatment (ADOPT) trial. J Clin Oncol (2009) 2.02
Age-related prognostic impact of different types of DNMT3A mutations in adults with primary cytogenetically normal acute myeloid leukemia. J Clin Oncol (2012) 1.98
Phase I study of vorinostat in combination with bortezomib for relapsed and refractory multiple myeloma. Clin Cancer Res (2009) 1.92
Circadian sensitivity to the chemotherapeutic agent cyclophosphamide depends on the functional status of the CLOCK/BMAL1 transactivation complex. Proc Natl Acad Sci U S A (2005) 1.91
Lentiviral vectors with two independent internal promoters transfer high-level expression of multiple transgenes to human hematopoietic stem-progenitor cells. Mol Ther (2003) 1.87
Aldehyde dehydrogenase 1 A1-positive cell population is enriched in tumor-initiating cells and associated with progression of bladder cancer. Cancer Epidemiol Biomarkers Prev (2010) 1.85
Kruppel-like factor 4 is essential for inflammatory monocyte differentiation in vivo. J Immunol (2008) 1.83
Epigenetic signatures of autism: trimethylated H3K4 landscapes in prefrontal neurons. Arch Gen Psychiatry (2011) 1.81
RUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and MicroRNA expression signatures. J Clin Oncol (2012) 1.79
miR-3151 interplays with its host gene BAALC and independently affects outcome of patients with cytogenetically normal acute myeloid leukemia. Blood (2012) 1.77
CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients. J Clin Invest (2016) 1.75
Improved methods for the generation of human gene knockout and knockin cell lines. Nucleic Acids Res (2005) 1.75
Microarray and serial analysis of gene expression analyses identify known and novel transcripts overexpressed in hematopoietic stem cells. Cancer Res (2004) 1.68
HES1 inhibits cycling of hematopoietic progenitor cells via DNA binding. Stem Cells (2006) 1.66
Role of breast cancer resistance protein (BCRP/ABCG2) in cancer drug resistance. Biochem Pharmacol (2012) 1.65
Small nucleolar RNA signatures as biomarkers for non-small-cell lung cancer. Mol Cancer (2010) 1.56
Analysis of the gut microbiota in the old order Amish and its relation to the metabolic syndrome. PLoS One (2012) 1.56
Subdural hematomas in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia receiving imatinib mesylate in conjunction with systemic and intrathecal chemotherapy. Leuk Lymphoma (2011) 1.53
Racial differences in presentation, referral and treatment patterns and survival in adult patients with acute myeloid leukemia: a single-institution experience. Leuk Res (2011) 1.49
Reduced incidence of acute and chronic graft-versus-host disease with the addition of thymoglobulin to a targeted busulfan/cyclophosphamide regimen. Biol Blood Marrow Transplant (2006) 1.47
Connective tissue growth factor (CTGF) expression and outcome in adult patients with acute lymphoblastic leukemia. Blood (2007) 1.46
Identification of genes with abnormal expression changes in acute myeloid leukemia. Genes Chromosomes Cancer (2008) 1.46
Cyclosporin A is a broad-spectrum multidrug resistance modulator. Clin Cancer Res (2005) 1.45
Leukemic blast and natural killer cell P-glycoprotein function and inhibition in a clinical trial of zosuquidar infusion in acute myeloid leukemia. Leuk Res (2008) 1.43
Rare hemoglobinopathy presenting as progressive dyspnea. Am J Hematol (2010) 1.43
Drug resistance: still a daunting challenge to the successful treatment of AML. Drug Resist Updat (2012) 1.35
Epigenetics meets genetics in acute myeloid leukemia: clinical impact of a novel seven-gene score. J Clin Oncol (2013) 1.34
Outcome of induction and postremission therapy in younger adults with acute myeloid leukemia with normal karyotype: a cancer and leukemia group B study. J Clin Oncol (2004) 1.32
C/EBPalpha directs monocytic commitment of primary myeloid progenitors. Blood (2006) 1.31
Mutations of the Wilms tumor 1 gene (WT1) in older patients with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. Blood (2010) 1.30
Comparison of reduced-intensity hematopoietic cell transplantation with chemotherapy in patients age 60-70 years with acute myelogenous leukemia in first remission. Biol Blood Marrow Transplant (2011) 1.29
A dinucleotide deletion in CD24 confers protection against autoimmune diseases. PLoS Genet (2007) 1.25
Dopamine D2-like antagonists induce chromatin remodeling in striatal neurons through cyclic AMP-protein kinase A and NMDA receptor signaling. J Neurochem (2004) 1.25
Malaria-infected mice are cured by a single oral dose of new dimeric trioxane sulfones which are also selectively and powerfully cytotoxic to cancer cells. J Med Chem (2009) 1.23
The structural and accessory proteins M, ORF 4a, ORF 4b, and ORF 5 of Middle East respiratory syndrome coronavirus (MERS-CoV) are potent interferon antagonists. Protein Cell (2013) 1.23
Magnetic enrichment of bronchial epithelial cells from sputum for lung cancer diagnosis. Cancer (2008) 1.21
The tyrosine kinase inhibitor imatinib mesylate enhances the efficacy of photodynamic therapy by inhibiting ABCG2. Clin Cancer Res (2007) 1.21
Differences in prognostic factors and outcomes in African Americans and whites with acute myeloid leukemia. Blood (2004) 1.20
Donor statin treatment protects against severe acute graft-versus-host disease after related allogeneic hematopoietic cell transplantation. Blood (2009) 1.19
Taxane-based reversal agents modulate drug resistance mediated by P-glycoprotein, multidrug resistance protein, and breast cancer resistance protein. Mol Cancer Ther (2003) 1.18
Chromatin alterations associated with down-regulated metabolic gene expression in the prefrontal cortex of subjects with schizophrenia. Arch Gen Psychiatry (2005) 1.17
Innate signals overcome acquired TCR signaling pathway regulation and govern the fate of human CD161(hi) CD8α⁺ semi-invariant T cells. Blood (2011) 1.16
Personalized synthetic lethality induced by targeting RAD52 in leukemias identified by gene mutation and expression profile. Blood (2013) 1.16
Targeted manipulation of mammalian genomes using designed zinc finger nucleases. Biochem Biophys Res Commun (2009) 1.15
Deferasirox reduces serum ferritin and labile plasma iron in RBC transfusion-dependent patients with myelodysplastic syndrome. J Clin Oncol (2012) 1.15
Prevalence and significance of vitamin D deficiency in multiple myeloma patients. Br J Haematol (2008) 1.14
p53-inducible ribonucleotide reductase (p53R2/RRM2B) is a DNA hypomethylation-independent decitabine gene target that correlates with clinical response in myelodysplastic syndrome/acute myelogenous leukemia. Cancer Res (2008) 1.14
VX-710 (biricodar) increases drug retention and enhances chemosensitivity in resistant cells overexpressing P-glycoprotein, multidrug resistance protein, and breast cancer resistance protein. Clin Cancer Res (2004) 1.13
Outcomes of acute leukemia patients transplanted with naive T cell-depleted stem cell grafts. J Clin Invest (2015) 1.13
Low expression of MN1 associates with better treatment response in older patients with de novo cytogenetically normal acute myeloid leukemia. Blood (2011) 1.12
Linezolid-resistant Enterococcus faecalis isolated from a cord blood transplant recipient. J Clin Microbiol (2004) 1.11
Outcome of older patients with acute myeloid leukemia: an analysis of SEER data over 3 decades. Cancer (2013) 1.11
Combined genetic analysis of sputum and computed tomography for noninvasive diagnosis of non-small-cell lung cancer. Lung Cancer (2009) 1.11
Genomic profiling of myeloid sarcoma by array comparative genomic hybridization. Genes Chromosomes Cancer (2005) 1.10
Selecting genes by test statistics. J Biomed Biotechnol (2005) 1.09
Male DNA in female donor apheresis and CD34-enriched products. Blood (2003) 1.09
Alterations in cell growth and signaling in ErbB3 binding protein-1 (Ebp1) deficient mice. BMC Cell Biol (2008) 1.08
Two homozygous nonsense mutations of GNPTAB gene in two Chinese families with mucolipidosis II alpha/beta using targeted next-generation sequencing. Genomics (2013) 1.07
TEL-AML1, expressed from t(12;21) in human acute lymphocytic leukemia, induces acute leukemia in mice. Cancer Res (2002) 1.06
Pharmacologically regulated Fas-mediated death of adoptively transferred T cells in a nonhuman primate model. Blood (2003) 1.06
Effects of HMGN variants on the cellular transcription profile. Nucleic Acids Res (2011) 1.05
Arsenic trioxide affects signal transducer and activator of transcription proteins through alteration of protein tyrosine kinase phosphorylation. Clin Cancer Res (2006) 1.05
ErbB3 binding protein 1 represses metastasis-promoting gene anterior gradient protein 2 in prostate cancer. Cancer Res (2010) 1.05
Coordinated cell type-specific epigenetic remodeling in prefrontal cortex begins before birth and continues into early adulthood. PLoS Genet (2013) 1.05
Malaria-infected mice live until at least day 30 after a new monomeric trioxane combined with mefloquine are administered together in a single low oral dose. J Med Chem (2009) 1.04